This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Eric G. Romanowski, MS; Laurie A. Roba, MD; Lee Wiley, MD; Trinita Araullo-Cruz, PhD; Y. Jerold Gordon, MD

Arch Ophthalmol. 1996;114(5):581-585.

Abstract
Objective
To evaluate the effects of Pred Forte (prednisolone acetate; Allergan Pharmaceutical, Irvine, Calif) on the replication of different adenoviral serotypes in vitro and in the adenovirus type 5/New Zealand rabbit ocular model.

Methods
The 50% inhibitory doses of Pred Forte and its components were determined for common ocular serotypes. The effects of continuous topical treatment with Pred Forte for 18 days were evaluated (eg, conjunctivitis, subepithelial immune infiltrates, and serial ocular viral titers) in the adenovirus 5/New Zealand rabbit ocular model.

Results
Pred Forte and prednisolone acetate inhibited adenoviruses 1, 5, 8, and 19 in vitro. In vivo, 1% Pred Forte significantly reduced conjunctivitis (P=.04) and subepithelial infiltrates (P=.02), but enhanced viral replication (P=.01) on days 9 to 21 and increased the duration of viral shedding (P<.001).

Conclusions
Despite demonstrated anti-inflammatory and anti-immune effects, prolonged treatment of acute adenoviral infections with topical Pred Forte is not recommended because of the enhanced risks of viral transmission and community epidemics.

Author Affiliations
From the Campbell Laboratory for Infectious Eye Diseases, Department of Ophthalmology, University of Pittsburgh (Pa) School of Medicine. The authors have no proprietary interest in the companies or products mentioned in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The In Vitro and In Vivo Evaluation of ddC as a Topical Antiviral for Ocular Adenovirus Infections
Romanowski et al.
IOVS 2009;50:5295-5299.
ABSTRACT | FULL TEXT  

Effects of Diclofenac or Ketorolac on the Inhibitory Activity of Cidofovir in the Ad5/NZW Rabbit Model
Romanowski and Gordon
IOVS 2001;42:158-162.
ABSTRACT | FULL TEXT  

Efficacy of Topical Cidofovir on Multiple Adenoviral Serotypes in the New Zealand Rabbit Ocular Model
Romanowski and Gordon
IOVS 2000;41:460-463.
ABSTRACT | FULL TEXT  

The Effects of Topical Nonsteroidal Anti-inflammatory Drugs on Adenoviral Replication
Gordon et al.
Arch Ophthalmol 1998;116:900-905.
ABSTRACT | FULL TEXT